Skip to main content

Human Embryonic Stem Cell Market 2019: Business Opportunities and Industry Analysis - BD, Takara Bio Inc., Geron Corporation, Thermo Fisher Scientific, ViaCyte, CellGenix GmbH, Vitrolife, and Lonza

Press release   •   Jul 02, 2019 11:01 IST

The global human embryonic stem cell market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading human embryonic stem cell market players and offers key trends and opportunities in the market.

The human embryonic stem cells are obtained from the undifferentiated inner mass cell of the human embryo and human fetal tissue. The human embryonic stem cell can replicate indefinitely and produce non-regenerative tissue such as myocardial and neural cells. This potential of human embryonic stem cell allows them to provide an unlimited amount of tissue for transplantation therapies to treat a wide range of degenerative diseases. Hence, human embryonic stem cells are used in the treatment of various diseases such as Alzheimer's disease, cancer, blood and genetic disorders related to the immune system and others.

Get PDF sample copy:

The global human embryonic stem cell market is expected to grow in upcoming years, factors driving the growth of market are rise in incidences of neurological disorders, increase in investment by government and other organization for research activities, awareness among people about stem cell therapeutic potency for disease treatment. On the other hand emerging stem cell banking services is expected to offer lucrative opportunities in growth of human embryonic stem cell market.

Top Dominating Key Players: 

  • BD
  • Takara Bio Inc.
  • Geron
  • Thermo Fisher Scientific Inc.
  • ViaCyte, Inc.
  • R&D Systems, Inc.
  • CellGenix GmbH
  • Vitrolife
  • Lonza

The report analyzes factors affecting human embryonic stem cell market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the human embryonic stem cell market in these regions.

The global human embryonic stem cell market is segmented on the basis of product type, application and end user. Based on product type, the market is segmented as totipotent stem cell, pluripotent stem cell and unipotent stem cell. On the basis of application, the global human embryonic stem cell market is segmented into regenerative medicine, stem cell biology research, tissue engineering and toxicology testing. Based on end users, the market is segmented as therapeutics companies, cell & tissue banks, tools & reagents companies and others.

Inquire for Discount:

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global human embryonic stem cell market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The human embryonic stem cell market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region. 

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.

Comments (0)

Add comment


By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.